Heck Capital Advisors LLC Has $405,000 Stock Position in Novartis AG $NVS

Heck Capital Advisors LLC raised its position in Novartis AG (NYSE:NVS) by 7.9% during the second quarter, HoldingsChannel.com reports. The firm owned 3,350 shares of the company’s stock after buying an additional 244 shares during the quarter. Heck Capital Advisors LLC’s holdings in Novartis were worth $405,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Essex Savings Bank raised its position in Novartis by 1.9% during the second quarter. Essex Savings Bank now owns 4,611 shares of the company’s stock valued at $558,000 after acquiring an additional 85 shares in the last quarter. Physician Wealth Advisors Inc. increased its stake in shares of Novartis by 5.8% during the 2nd quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company’s stock worth $186,000 after purchasing an additional 85 shares during the last quarter. Gallacher Capital Management LLC raised its holdings in shares of Novartis by 1.7% during the 2nd quarter. Gallacher Capital Management LLC now owns 5,371 shares of the company’s stock valued at $650,000 after purchasing an additional 92 shares in the last quarter. Ascent Group LLC lifted its stake in shares of Novartis by 0.7% in the 2nd quarter. Ascent Group LLC now owns 14,121 shares of the company’s stock valued at $1,709,000 after purchasing an additional 97 shares during the last quarter. Finally, Sage Rhino Capital LLC boosted its holdings in Novartis by 1.2% in the second quarter. Sage Rhino Capital LLC now owns 8,120 shares of the company’s stock worth $983,000 after purchasing an additional 99 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on NVS. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a report on Thursday, August 21st. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price objective on the stock in a research note on Friday, August 8th. Wall Street Zen cut Novartis from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. The Goldman Sachs Group reissued a “sell” rating and issued a $118.00 price target (down previously from $119.00) on shares of Novartis in a research report on Friday, September 12th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $120.33.

Novartis Stock Performance

Shares of NYSE NVS opened at $132.35 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The business’s 50 day moving average is $123.90 and its two-hundred day moving average is $117.38. The company has a market cap of $279.58 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.83 and a beta of 0.64. Novartis AG has a 12 month low of $96.06 and a 12 month high of $133.55.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The company had revenue of $14.05 billion during the quarter, compared to analysts’ expectations of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%.Novartis’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.97 earnings per share. On average, equities analysts expect that Novartis AG will post 8.45 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.